Feb 14 (Reuters) - Biotherapeutics company CSL Ltd reported a 35 percent rise in its first half profit on Wednesday and upgraded its earnings guidance for the fiscal year.
Net profit after tax was $1.1 billion, the company said, compared with $805.5 million a year ago.
CSL also upgraded its fiscal 2018 earnings guidance to about $1.55 billion-$1.60 billion from an earlier forecast of $1.48 billion-$1.55 billion.
The company's stock rose as much as 6 percent after it announced its results and is among the top gainers on the benchmark Australian index .
(Reporting by Sumeet Gaikwad in Bengaluru; Editing by Paul Tait)
Disclaimer: The views expressed in this article are those of the author and may not reflect those of Kitco Metals Inc. The author has made every effort to ensure accuracy of information provided; however, neither Kitco Metals Inc. nor the author can guarantee such accuracy. This article is strictly for informational purposes only. It is not a solicitation to make any exchange in commodities, securities or other financial instruments. Kitco Metals Inc. and the author of this article do not accept culpability for losses and/ or damages arising from the use of this publication.